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Summary
 
Tumor necrosis factor (TNF) is a central mediator of a number of important pathologies such
as the systemic inflammatory response syndrome. Administration of high TNF doses induces
acute anorexia, metabolic derangement, inflammation, and eventually shock and death. The in
vivo effects of TNF are largely mediated by a complex network of TNF-induced cytokines and
hormones acting together or antagonistically. Since TNF also induces leptin, a hormone se-
creted by adipocytes that modulates food intake and metabolism, we questioned the role of
leptin in TNF-induced pathology. To address this question, we tested mouse strains that were
defective either in leptin gene (
 
ob/ob
 
) or in functional leptin receptor gene (
 
db/db
 
), and made
use of a receptor antagonist of leptin. 
 
Ob/ob
 
 and 
 
db/db
 
 mice, as well as normal mice treated
with antagonist, exhibited increased sensitivity to the lethal effect of TNF. Exogenous leptin
afforded protection to TNF in 
 
ob/ob
 
 mice, but failed to enhance the protective effect of endog-
enous leptin in normal mice. We conclude that leptin is involved in the protective mechanisms
that allow an organism to cope with the potentially autoaggressive effects of its immune system.
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T
 
umor necrosis factor (TNF) is a pleiotropic cytokine
with potent antitumor activity; however, it is also in-
volved in the pathogenesis of many inflammatory diseases.
Above all, TNF is a central mediator of the potentially le-
thal systemic inflammatory response syndrome (1). A single
injection of TNF into animals causes acute anorexia,
weight loss, metabolic derangement, hypotension, and, at
very high doses, shock and death as a result of a widespread
systemic inflammatory reaction (2, 3). However, prolonged
treatment with lower doses of TNF results in tachyphylaxis
and tolerance (4–6). These effects are largely mediated by a
complex network of cytokines, hormones, and low-molec-
ular weight mediators induced by TNF (7). This network
is not only responsible for the deleterious outcome, but also
for the induction of often more complex endogenous pro-
tection mechanisms whose function allows the organism to
cope with the potentially autoaggressive consequences of
immune/inflammatory reactions. Glucocorticoid hormones
represent the most powerful antiinflammatory arm (8),
whereas some proinflammatory cytokines, such as IL-1 and
IL-6, play a dual role by also contributing to protective
mechanisms via induction of acute-phase proteins (9).
Some acute-phase proteins act as protease inhibitors to
limit the destructive effects of TNF-induced proteases (10,
11). The exact significance of each of these mediators is far
from established. In this study we wanted to investigate the
role of leptin, which was described as being induced by
TNF (12, 13). Leptin is the product of the 
 
ob
 
 gene associ-
ated with obesity (14). Mutant mice with a defective leptin
gene (
 
ob/ob
 
) or leptin receptor gene (
 
db/db
 
) exhibit hyper-
phagia, reduced energy expenditure, and obesity (15, 16).
Administration of leptin was found to reduce food intake
in both normal and 
 
ob/ob
 
 mice (17, 18). Recently, a spe-
cific receptor antagonist of leptin was obtained by intro-
ducing a point mutation into the human leptin gene (19).
This leptin mutein binds to the leptin receptor but fails to
transduce a signal. When injected into normal mice, the
leptin antagonist induced weight gain (19). Given the pos-
sible link between TNF and leptin on the production level,
we speculated on the role of leptin in TNF-induced effects.
Using mutant mouse strains and antagonist, we investigated
the role of endogenous leptin in TNF-induced lethality.
 
Materials and Methods
 
Animals.
 
 Specific pathogen–free female C57BL/6 mice, 8–12
wk old at the beginning of the experiments, were obtained from
Charles River Labs. Specific pathogen–free C57BL/6J mice
(referred to as wild-type [wt]), C57BL/6-ob mice (referred to as
 
ob/ob
 
), and C57BL/Ks-db mice (further referred to as 
 
db/db
 
) 
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were obtained from Harlan/Olac and The Jackson Laboratory.
The animals were housed in a temperature-controlled environ-
ment with 12-h light/dark cycles and received food and water ad
libitum. All experiments were performed according to the Euro-
pean Union Guidelines on Animal Care and Use.
 
Reagents.
 
 Recombinant murine TNF (mTNF), produced by
 
Escherichia coli
 
 containing an appropriate expression plasmid (20),
was purified to apparent homogeneity. The specific activity was
2
 
 3 
 
10
 
8
 
 IU/mg as determined in a cytotoxicity assay on L929
cells (21). Reference mTNF (code 88/532) was from the Na-
tional Institute for Biological Standards and Control (Potters Bar,
UK). The endotoxin content was 
 
,
 
0.2 ng/mg, as assessed by a
chromogenic 
 
Limulus amebocyte
 
 lysate assay (Coatest; Chromoge-
nix, Stockholm, Sweden). Human wt leptin was produced by
baculovirus-infected insect cells (22) and purified on an immu-
noaffinity column as described previously (19); the endotoxin
content amounted to 2.5 ng/mg. R128Q, an antagonist of hu-
man leptin, was created by site-directed mutagenesis and selected
for its inhibitory activity on leptin sensitive-BAF3 1423 cells (19);
the endotoxin content amounted to 2.1 ng/mg. 2A5, a mono-
clonal antibody directed against human leptin, was purified from
hybridoma supernatant (19); the endotoxin content was 0.09 ng/
mg protein. All reagents were diluted in endotoxin-free PBS be-
fore injection.
 
Treatment.
 
 In experiments involving comparison of the sen-
sitivity of different mouse strains, mice were challenged with sub-
lethal doses of mTNF given intravenously. mTNF is lethal in
normal mice at a dose of 
 
z
 
20 
 
m
 
g (23). Survival was monitored
for up to 60 h. There were no further deaths during the 1-wk pe-
riod of follow-up. In experiments assessing the effect of leptin or
leptin antagonist in TNF toxicity, mice were pretreated intraperi-
toneally with either agent in combination with an antibody
(twice daily for 2 d and immediately before the challenge with
varying doses of mTNF intravenously). Doses of leptin and lep-
tin antagonist R128Q were 100 
 
m
 
g/mouse; doses of antibody
2A5 were 1 mg/mouse or 100 
 
m
 
g/mouse. Leptin and R128Q
are cleared from the circulation very rapidly. The antibody 2A5
raised against human leptin also binds to R128Q and dramatically
prolongs the biological half-life of both wt and mutant leptin
mice. It was also demonstrated that the biological effects of leptin
and the antagonist in wt mice are only seen in the presence of
antibody (19). For this reason, antibody was coadministered
whenever leptin or R128Q were used. The injection volumes
were 0.5 ml in the case of intraperitoneal and 0.2 ml in the case
of intravenous administration.
 
Statistics.
 
 The significance of differences in survival time was
analyzed by a Log-rank test for curve comparison using a Graph-
Pad Prism computer program (GraphPad Software). In all cases,
 
 P 
 
,
 
0.05 was considered to be significantly different.
 
Results
 
Mice Lacking Leptin-signaling Are Highly Sensitive to the Le-
thal Toxicity of mTNF. 
 
To assess the role of endogenous
leptin induced by TNF, we first tested mutant mouse
strains lacking a functional leptin system. Both 
 
ob/ob
 
 and
 
db/db
 
 mice were challenged with 500 
 
m
 
g/kg mTNF. This
dose of TNF, which does not cause lethality in wt mice,
resulted in 100 and 80% lethality in 
 
ob/ob
 
 and 
 
db/db
 
 mice,
respectively (Fig. 1). Therefore, both 
 
ob/ob
 
 and 
 
db/db
 
 mice
are far more sensitive to the lethal effect of mTNF (
 
P
 
 
 
5
 
0.0001 
 
ob/ob
 
 versus wt;
 
 P 
 
5 
 
0.0006 
 
db/db
 
 versus wt). This
suggests that a functional leptin system protects against a
low dose of mTNF.
 
Exogenous Leptin Protects ob/ob Mice from the Lethal Toxic-
ity of mTNF.
 
We tested whether exogenous leptin can
protect 
 
ob/ob
 
 mice lacking endogenous leptin. Leptin and
2A5 antibody were administered twice daily for 2 d and at
the same time as a challenge with mTNF. In agreement
with the previous experiment, 
 
ob/ob
 
 mice exhibited signifi-
cantly higher sensitivity to TNF as compared with wt mice
(Fig. 2;
 
 P 
 
5 
 
0.0025 versus wt receiving 2A5 alone). 
 
Ob/ob
 
mice pretreated with leptin showed resistance comparable
to that of wt, and the survival time was significantly longer
(
 
P
 
 
 
5 
 
0.0079 versus 
 
ob/ob
 
 receiving 2A5 alone). There was
Figure 1.Sensitivity of ob/ob and db/db mice to mTNF-induced lethal-
ity. Mice (wt, ob/ob and db/db) were challenged with 500 mg/kg mTNF
intravenously. The percentage of survival was plotted as a function of
time (hours after challenge). n 5 10 (wt) and 5 (ob/ob and db/db). s, wt;
h, ob/ob; n, db/db. ****P 5 0.0001 (wt versus ob/ob); ***P 5 0.0006 (wt
versus db/db). The results shown are representative of three independent
experiments.
Figure 2.Effect of leptin pretreatment in ob/ob mice receiving a lethal
challenge with mTNF. Mice (wt and ob/ob) were pretreated as described
in Materials and Methods. Doses of 2A5 antibody and leptin were both
100 mg/mouse. Mice were challenged with 500 mg/kg mTNF. The per-
centage of survival was plotted as a function of time (hours after chal-
lenge). For each group, n 5 5. s, 2A5 in wt mice; h, 2A5 in ob/ob mice;
n, leptin 1 2A5 in ob/ob mice. **P 5 0.0025 (wt versus ob/ob); *P 5
0.0079 (ob/ob-2A5 versus ob/ob-leptin). The results shown are representa-
tive of three independent experiments. 
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no significant difference between 
 
ob/ob
 
 mice pretreated
with leptin and wt mice. These data confirm our previous
evidence that endogenous leptin is protective against the
lethal toxicity of TNF and demonstrate that the lack of en-
dogenous leptin can be compensated by administration of
exogenous leptin.
 
Leptin Antagonist Sensitizes Normal Mice to the Lethal Tox-
icity of TNF.
 
If sensitization to the toxic effect of TNF in
the genetically defective leptin system is fully attributable to
leptin (and not to the consequence of secondary effects,
such as obesity, elevated levels of insulin, or corticoids), the
same sensitization should be obtained in normal lean mice,
where the function of leptin is blocked. Therefore, we ex-
amined
 
 
 
the effect of leptin and leptin antagonist R128Q on
the lethal toxicity of mTNF in normal mice. We tested
two doses of mTNF that would result in 
 
z
 
50 and 0% le-
thality, respectively, in normal mice. Mice were pretreated
with leptin or R128Q antagonist, both in the presence of
100 
 
m
 
g 2A5 antibody per mouse. Treatment with R128Q
clearly sensitized mice to TNF toxicity, since 60% died
even in response to a low dose of mTNF (Fig. 3 A;
 
 P 
 
5
 
0.0008, a significant difference compared with the control
group receiving 2A5 alone). Moreover, treatment with
R128Q and a higher dose of TNF increased the death toll
from 50 to 100%, and the survival time was significantly re-
duced (Fig. 3 B;
 
 P 
 
5 
 
0.0063, compared with the control
group receiving 2A5 alone). On the other hand, exogenous
leptin did not provide any further protection, suggesting
that the endogenous leptin level is sufficient for a protec-
tive effect. The difference observed between mice pre-
treated with leptin antagonist and those with antibody
alone is due to the functional level of leptin. These experi-
ments allow us to conclude that endogenous leptin protects
against TNF-induced lethality.
 
Discussion
 
The finding that endogenous leptin plays a protective
role against TNF-induced lethality suggests an entirely new
property to be attributed to this protein, namely immuno-
modulatory and antiinflammatory effects. Recently, it was
also reported that genetically obese rodents were more sus-
ceptible to endotoxin-induced liver injury (24). This could
be explained by increased sensitivity to TNF in the absence
of a functional leptin system as shown here. Although in-
creased production of certain proinflammatory cytokines
by leptin is reported (24, 25), these results rather point to a
possible impairment of the function of these cytokines by
leptin. A recent finding that leptin upregulates suppressors
of cytokine signaling 3 (26) supports such a speculation.
The protective role of leptin reminds us of another class of
TNF-induced hormones, namely glucocorticoids. Also in
this case, mice devoid of a functional glucocorticoid system
(by adrenalectomy or administration of a receptor antago-
nist) are highly sensitized to the toxic effects of TNF (27,
28). The fact that exogenous leptin is able to reverse the in-
creased sensitivity of mice lacking an active leptin system,
and that it is ineffective in further decreasing the sensitivity
of normal mice, indicates that the leptin levels after TNF
induction are high enough to obtain a maximal effect. This
is also similar to the situation with glucocorticoids, where
adding exogenous hormone could not improve survival in
sepsis; on the contrary, blocking the action of this hormone
by administering a receptor antagonist, even hours after
TNF administration, increased the lethality (28). TNF acti-
vates the hypothalamus pituitary-adrenal axis (HPAA), re-
sulting in a release of glucocorticoids, which in turn atten-
uate the immune/inflammatory reaction (29). Both leptin
and glucocorticoids induced by TNF itself seem to exert a
regulatory negative feedback to prevent the potentially
harmful consequences of the proinflammatory cascade. The
presence of a bidirectional relationship is suggestive of a co-
ordinated function. Glucocorticoids elevate the leptin level
(30), whereas leptin elicits an effect on HPAA and alters
the circulating glucocorticoid levels (31). Besides, leptin
signaling might lead to an enhanced level of another antiin-
Figure 3.Effect of leptin and leptin antagonist on mTNF-induced le-
thality. C57BL/6 mice were pretreated with leptin (100 mg/mouse) or
R128Q (100 mg/mouse) in combination with 2A5 antibody (100 mg/
mouse) as described in Materials and Methods. Mice were challenged
with a low dose (A, 375 mg/kg) or a high dose (B, 750 mg/kg) of mTNF.
The percentage of survival was plotted as a function of time (hours after
challenge). Each group consisted of 13 mice. The result is a cumulative
sum of two independent experiments. (A) s, 2A5; h, leptin 1 2A5; n,
R128Q 1 2A5; ***P 5 0.0008 (2A5 versus R128Q 1 2A5); (B) d, 2A5;
j, leptin 1 2A5; m, R128Q 1 2A5. **P 5 0.0063 (2A5 versus R128Q 1
2A5).210 Protection by Leptin against TNF Lethality
flammatory hormone, a-melanocyte-stimulating hormone
(a-MSH; reference 32). It is highly likely that the protec-
tive effect of leptin is mediated by a-MSH, which was
shown to protect against endotoxin-induced liver injury
and mortality (33, 34). The action of a-MSH resembles
that of glucocorticoids in that it inhibits the production of
proinflammatory mediators (33, 35). Thus a picture emerges
that leptin, acting on two parallel antiinflammatory axes,
modulates the defence of the body against the TNF-induced
inflammatory cascade (Fig. 4). Both a-MSH and corti-
cotrophins are derived from the proopiomelanocortin gene
and partly share common receptor subtypes. Thus these
two arms are also interrelated. One of the receptors for
a-MSH, melanocortin-1 receptor, is found on neutrophils
and macrophages, and is postulated to mediate the anti-
inflammatory effects of a-MSH (33, 35). However, the
antiinflammatory effect of a-MSH involves both central
and peripheral signals (36), suggesting an involvement of
yet another receptor subtype that mediates central signal-
ing. Quite intriguingly, it was demonstrated that melano-
cortin-4 receptor, another MSH receptor, mediated the
anorectic effect of leptin (37). Whether or not this receptor
type also plays a role in the potentially antiinflammatory
function of leptin should be addressed in the future. The
fact that db/db mice lacking the functional long form of the
leptin receptor (38) are also sensitized to TNF indicates that
signaling through this type of receptor is essential for the
protective effect. The leptin receptor belongs to the class-I
cytokine receptor family (16), which suggests an ancestral
link between the cytokine system and leptin. Furthermore,
leptin itself is structurally related to the cytokines (39). It is
intriguing that there is an overlap between the activities of
TNF and leptin (Fig. 4). Both TNF and leptin activate the
HPAA and melanocortin system (35), and it appears that
leptin provides a redundant way to ensure protection. On
the other hand, HPAA exerts a negative feedback on the
production of TNF and a positive feedback on leptin pro-
duction. In this way, the protective pathway induced by
TNF can be amplified in the absence of TNF.
We also found that TNF can still induce weight loss in
the absence of a functional leptin system (results not
shown). This rules out the mediation of leptin in this effect.
Recently, a similar result on endotoxin-induced anorexia
was published using ob/ob and db/db mice (39). In this case,
TNF is presumably a principal mediator, and the study
confirms our finding. Therefore, TNF and leptin seem to
control the body weight independently. It is not unlikely
that both induce either a common mediator or partly com-
mon signaling pathways. Recently, a defective melanocor-
tin-4 receptor was shown to cause agouti-type obesity (40).
Considering the role of this receptor in leptin-induced an-
orexia (37), it is extremely tempting to speculate that it is
part of the common pathway. It should be noted that an-
orectic factors, such as melanocortins and corticotrophin-
releasing factor, can be independently activated by TNF
and leptin (Fig. 4). Here again, factors involved in the im-
mune/neuroendocrine network form a partly common and
partly distinct network.
In conclusion, the finding of a protective role for leptin
against TNF toxicity extends the picture of communica-
tion between the immune system and the neuroendocrine
system. It is attractive to speculate that the leptin system,
with its structural relationship to the cytokine system (41)
and functional similarity to glucocorticoids, evolved to
form a partly redundant and partly distinct regulatory net-
work to maintain homeostasis both under physiological and
pathological conditions. Future studies will clarify the mo-
lecular basis underlying the communication among cyto-
kine/glucocorticoid/leptin systems.
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Figure 4.Immune neuroen-
docrine network involving TNF
and leptin. TNF induces a proin-
flammatory cascade on the one
hand and an antiinflammatory
protection mechanism on the
other hand. ®, induction; ¢, in-
hibition; Þ, binding to a recep-
tor. GCH, glucocorticoid hor-
mone; OB-R, leptin receptor
long form; MC2-R, melanocor-
tin-2 receptor; MCx-R, melano-
cortin-1 receptor or possibly
other subtypes.211 Takahashi et al. Brief Definitive Report
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